

Lise L Gluud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6923160/publications.pdf>

Version: 2024-02-01

209
papers

20,583
citations

26610

56
h-index

11601

135
g-index

228
all docs

228
docs citations

228
times ranked

20648
citing authors

#	ARTICLE	IF	CITATIONS
1	Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. <i>BMJ: British Medical Journal</i> , 2008, 336, 601-605.	2.4	2,174
2	Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses. <i>Annals of Internal Medicine</i> , 2001, 135, 982.	2.0	2,031
3	Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 842.	3.8	1,930
4	Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials. <i>Annals of Internal Medicine</i> , 2012, 157, 429.	2.0	880
5	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
6	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2012, 344, d7771-d7771.	2.4	731
7	Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. <i>International Journal of Epidemiology</i> , 2009, 38, 276-286.	0.9	708
8	Association of Funding and Conclusions in Randomized Drug Trials. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 921.	3.8	638
9	Bias in Clinical Intervention Research. <i>American Journal of Epidemiology</i> , 2006, 163, 493-501.	1.6	545
10	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <i>The Cochrane Library</i> , 2012, 2012, CD007176.	1.5	479
11	Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the <i>BMJ</i> . <i>BMJ: British Medical Journal</i> , 2002, 325, 249-249.	2.4	367
12	Artificial and Bioartificial Support Systems for Acute and Acute-on-Chronic Liver Failure. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 217.	3.8	344
13	Vitamin D supplementation for prevention of mortality in adults. <i>The Cochrane Library</i> , 2014, , CD007470.	1.5	329
14	Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. <i>BMJ: British Medical Journal</i> , 2004, 328, 1046.	2.4	324
15	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
16	Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. <i>Hepatology</i> , 2010, 51, 576-584.	3.6	252
17	Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta-Analysis.. <i>American Journal of Transplantation</i> , 2006, 6, 1578-1585.	2.6	230
18	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. <i>Diabetologia</i> , 2013, 56, 965-972.	2.9	199

#	ARTICLE	IF	CITATIONS
19	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. , 2008, , CD007176.		197
20	Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. <i>Pancreatology</i> , 2020, 20, 665-667.	0.5	190
21	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166125.	1.1	188
22	The window hypothesis: haemodynamic and non-haemodynamic effects of β -blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1. <i>Gut</i> , 2012, 61, 967-969.	6.1	180
23	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2019, 15, e8793.	3.2	176
24	Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 123-132.	1.9	168
25	The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1407-1415.	0.6	159
26	Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies. <i>British Journal of Nutrition</i> , 2007, 98, 17-25.	1.2	150
27	Evidence based diagnostics. <i>BMJ: British Medical Journal</i> , 2005, 330, 724-726.	2.4	149
28	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
29	Infection increases mortality in necrotizing pancreatitis: A systematic review and meta-analysis. <i>Pancreatology</i> , 2016, 16, 698-707.	0.5	146
30	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
31	Branched-chain amino acids for people with hepatic encephalopathy. <i>The Cochrane Library</i> , 2017, 5, CD001939.	1.5	136
32	Vitamin D supplementation for prevention of cancer in adults. <i>The Cochrane Library</i> , 2014, , CD007469.	1.5	128
33	Banding Ligation Versus Beta-Blockers as Primary Prophylaxis in Esophageal Varices: Systematic Review of Randomized Trials. <i>American Journal of Gastroenterology</i> , 2007, 102, 2842-2848.	0.2	126
34	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3346-3352.	4.3	125
35	Branched-chain amino acids for hepatic encephalopathy. , 2003, , CD001939.		116
36	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112

#	ARTICLE	IF	CITATIONS
37	Randomized clinical trials in Hepatology: Predictors of quality. <i>Hepatology</i> , 1999, 30, 1134-1138.	3.6	109
38	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 300-305.	2.2	107
39	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
40	Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. <i>The Cochrane Library</i> , 2012, , CD004544.	1.5	96
41	Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. <i>Liver International</i> , 2015, 35, 2072-2078.	1.9	93
42	Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials. <i>Journal of Nutrition</i> , 2013, 143, 1263-1268.	1.3	92
43	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 906-908.	2.2	90
44	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. <i>Metabolic Brain Disease</i> , 2013, 28, 221-225.	1.4	88
45	Tranexamic acid for upper gastrointestinal bleeding. <i>The Cochrane Library</i> , 2014, , CD006640.	1.5	88
46	Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 64, 908-922.	3.6	84
47	Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. <i>BMJ: British Medical Journal</i> , 2001, 323, 1151-1155.	2.4	83
48	Nonabsorbable disaccharides for hepatic encephalopathy. , 2004, , CD003044.		81
49	Terlipressin for hepatorenal syndrome. , 2012, , CD005162.		81
50	Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1155-1165.	1.9	79
51	Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 619-626.	1.9	73
52	Ursodeoxycholic Acid and Diets Higher in Fat Prevent Gallbladder Stones During Weight Loss: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1090-1100.e2.	2.4	73
53	Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. , 2016, 4, CD003044.		73
54	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 918-927.	1.2	72

#	ARTICLE	IF	CITATIONS
55	The Effect of Anti-Tumor Necrosis Factor Alpha Agents on Postoperative Anastomotic Complications in Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1423-1433.	0.7	67
56	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. <i>Molecular Metabolism</i> , 2020, 42, 101080.	3.0	66
57	Citation bias of hepato-biliary randomized clinical trials. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 407-410.	2.4	65
58	Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1153-1162.	1.9	65
59	Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. <i>Liver International</i> , 2015, 35, 2009-2016.	1.9	65
60	Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. <i>The Cochrane Library</i> , 2016, 2016, CD003044.	1.5	61
61	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , 2017, 65, 592-603.	3.6	60
62	Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. <i>Statistics in Medicine</i> , 2007, 26, 2745-2758.	0.8	59
63	L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. <i>The Cochrane Library</i> , 2019, 2019, CD012410.	1.5	59
64	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. <i>Journal of Internal Medicine</i> , 2016, 279, 485-493.	2.7	58
65	Meta-analysis: isosorbide mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 859-871.	1.9	57
66	Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. <i>Hepatology Research</i> , 2012, 42, 1008-1015.	1.8	55
67	Meta-analysis: antioxidant supplements for liver diseases – the Cochrane Hepato-Biliary Group. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 356-367.	1.9	54
68	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <i>Diabetes Care</i> , 2017, 40, 109-116.	4.3	54
69	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. <i>BMJ Open</i> , 2014, 4, e005325.	0.8	52
70	Benzodiazepine receptor antagonists for hepatic encephalopathy. , 2004, , CD002798.		50
71	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
72	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46

#	ARTICLE	IF	CITATIONS
73	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		44
74	Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 6-15.	1.9	44
75	Ribavirin plus interferon versus interferon for chronic hepatitis C. <i>The Cochrane Library</i> , 2010, , CD005445.	1.5	42
76	Acute kidney injury and hepatorenal syndrome in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 236-243.	1.4	42
77	Risk factors for and impact of respiratory failure on mortality in the early phase of acute pancreatitis. <i>Pancreatology</i> , 2016, 16, 756-760.	0.5	42
78	Systematic review: tranexamic acid for upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 752-758.	1.9	41
79	Antioxidant supplements for liver diseases. <i>The Cochrane Library</i> , 2011, , CD007749.	1.5	40
80	Tranexamic acid for upper gastrointestinal bleeding. , 2012, 1, CD006640.		39
81	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019, 70, e5.	1.8	39
82	Lower Risk of Recurrence After Mesh Repair Versus Non-Mesh Sutured Repair in Open Umbilical Hernia Repair: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Scandinavian Journal of Surgery</i> , 2019, 108, 187-193.	1.3	38
83	Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials. <i>American Journal of Gastroenterology</i> , 2006, 101, 842-847.	0.2	37
84	Large Variations in Risk of Hepatocellular Carcinoma and Mortality in Treatment Na ⁺ -ve Hepatitis B Patients: Systematic Review with Meta-Analyses. <i>PLoS ONE</i> , 2014, 9, e107177.	1.1	37
85	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <i>Sao Paulo Medical Journal</i> , 2015, 133, 164-165.	0.4	36
86	A Randomized Trial Assessing the Impact of Written Information on Outpatients' Knowledge About and Attitude Toward Randomized Clinical Trials. <i>Contemporary Clinical Trials</i> , 2000, 21, 223-240.	2.0	35
87	The Journal Impact Factor as a Predictor of Trial Quality and Outcomes: Cohort Study of Hepatobiliary Randomized Clinical Trials. <i>American Journal of Gastroenterology</i> , 2005, 100, 2431-2435.	0.2	35
88	Terlipressin versus other vasoactive drugs for hepatorenal syndrome. <i>The Cochrane Library</i> , 2017, 2017, CD011532.	1.5	34
89	Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. <i>The Cochrane Library</i> , 2017, 2017, CD005162.	1.5	32
90	Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection. <i>Archives of Internal Medicine</i> , 2005, 165, 2206.	4.3	31

#	ARTICLE	IF	CITATIONS
91	The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1081.	1.0	31
92	Misuse of Randomization: A Review of Chinese Randomized Trials of Herbal Medicines for Chronic Hepatitis B. <i>The American Journal of Chinese Medicine</i> , 2002, 30, 173-176.	1.5	30
93	Funding, disease area, and internal validity of hepatobiliary randomized clinical trials. <i>American Journal of Gastroenterology</i> , 2002, 97, 2708-2713.	0.2	30
94	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e003265.	0.8	30
95	Validity of randomized clinical trials in gastroenterology from 1964 to 2000. <i>Gastroenterology</i> , 2002, 122, 1157-1160.	0.6	29
96	Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2012, 2, e001313.	0.8	29
97	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		29
98	Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. <i>The Cochrane Library</i> , 2018, 2018, CD011510.	1.5	29
99	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
100	Ribavirin monotherapy for chronic hepatitis C. <i>The Cochrane Library</i> , 2009, , CD005527.	1.5	26
101	Physical exercise for people with cirrhosis. <i>The Cochrane Library</i> , 2018, 2018, CD012678.	1.5	26
102	Terlipressin for hepatorenal syndrome. , 2006, , CD005162.		24
103	Intestinal colonization with phylogenetic group B2 <i>Escherichia coli</i> related to inflammatory bowel disease: a systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1199-1207.	0.6	24
104	The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 448-451.	0.4	24
105	Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. <i>The Cochrane Library</i> , 2019, 6, CD012334.	1.5	24
106	Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. <i>Liver</i> , 2002, 22, 433-438.	0.1	23
107	Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD005441.	1.5	23
108	Endoscopic Necrosectomy Through Percutaneous Self-Expanding Metal Stents May Be a Promising Additive in Treatment of Necrotizing Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2456-2465.	1.1	23

#	ARTICLE	IF	CITATIONS
109	Cerebral Blood Flow and Metabolism in Hepatic Encephalopathyâ€”A Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 286-293.	0.4	22
110	Nonalcoholic Fatty Liver Disease Impairs the Liverâ€™Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. <i>Hepatology Communications</i> , 2020, 4, 1610-1623.	2.0	22
111	Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?. <i>Medical Hypotheses</i> , 2013, 81, 871-874.	0.8	21
112	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3783.	1.0	21
113	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 908-915.	1.8	20
114	Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. <i>Journal of Hepatology</i> , 2005, 43, 984-989.	1.8	19
115	Systematic review with metaâ€™analyses of studies on the association between cirrhosis and liver metastases. <i>Hepatology Research</i> , 2011, 41, 618-625.	1.8	19
116	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. <i>BMJ Open</i> , 2013, 3, e003417.	0.8	19
117	Predictors of Health-Related Quality of Life in Outpatients with Cirrhosis: Results from a Prospective Cohort. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-6.	2.0	19
118	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2042-2049.	1.8	18
119	Determining a healthy reference range and factors potentially influencing PRO-C3 â€™ A biomarker of liver fibrosis. <i>JHEP Reports</i> , 2021, 3, 100317.	2.6	18
120	Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. <i>EClinicalMedicine</i> , 2022, 45, 101332.	3.2	18
121	Ribavirin plus interferon versus interferon for chronic hepatitis C. , 2005, , CD005445.		17
122	Development of a combined database for metaâ€™epidemiological research. <i>Research Synthesis Methods</i> , 2010, 1, 212-225.	4.2	17
123	Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. <i>Patient Preference and Adherence</i> , 2014, 8, 331.	0.8	16
124	Update on the Therapeutic Management of Hepatic Encephalopathy. <i>Current Gastroenterology Reports</i> , 2018, 20, 21.	1.1	16
125	Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. <i>The Cochrane Library</i> , 2010, , CD004888.	1.5	15
126	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1522-1528.	1.4	15

#	ARTICLE	IF	CITATIONS
127	Ribavirin with or without alpha interferon for chronic hepatitis C. The Cochrane Library, 2002, , CD002234.	1.5	14
128	Characteristics of randomised trials on diseases in the digestive system registered in ClinicalTrials.gov: a retrospective analysis. BMJ Open, 2011, 1, e000309-e000309.	0.8	14
129	Dopamine agents for hepatic encephalopathy. The Cochrane Library, 2014, , CD003047.	1.5	14
130	Impaired Follistatin Secretion in Cirrhosis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3395-3400.	1.8	14
131	Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. The Cochrane Library, 2017, 2017, CD002798.	1.5	14
132	Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study. United European Gastroenterology Journal, 2020, 8, 68-76.	1.6	14
133	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine, 2020, 9, 3213.	1.0	14
134	Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. Nature Communications, 2022, 13, .	5.8	14
135	Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. American Journal of Gastroenterology, 2009, 104, 2335-2341.	0.2	13
136	Meta-analyses on Viral Hepatitis. Infectious Disease Clinics of North America, 2009, 23, 315-330.	1.9	13
137	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). The Cochrane Library, 2017, 2017, CD011646.	1.5	13
138	Characterisation of the fibroinflammatory process involved in progression from acute to chronic pancreatitis: study protocol for a multicentre, prospective cohort study. BMJ Open, 2019, 9, e028999.	0.8	13
139	Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices. The Cochrane Library, 2019, 6, CD012673.	1.5	13
140	Evaluation of local instillation of antibiotics in infected walled-off pancreatic necrosis. Pancreatology, 2018, 18, 642-646.	0.5	12
141	Endoscopic treatment with transmural drainage and necrosectomy for walled-off necrosis provides favourable long-term outcomes on pancreatic function. United European Gastroenterology Journal, 2020, 8, 552-558.	1.6	10
142	Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitis C " an updated Cochrane review. Alimentary Pharmacology and Therapeutics, 2010, 32, 840-850.	1.9	9
143	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open, 2013, 3, e003834.	0.8	9
144	The cost of endoscopic treatment for walled-off pancreatic necrosis. Pancreatology, 2019, 19, 828-833.	0.5	9

#	ARTICLE	IF	CITATIONS
145	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2017-2026.	2.2	9
146	Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1444.	0.2	8
147	Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2012, 2, e001803.	0.8	7
148	Prognosis of patients with ascites after PleurX insertion: an observational study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 340-344.	0.6	7
149	The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 8-8.	1.5	7
150	Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2020, 8, 1642-1650.	0.3	7
151	Cross-talk between the Liver, Heart and Kidney – another Piece in the Puzzle. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 119-121.	0.5	7
152	Reply to: “Adding embolization to TIPS implantation: A better therapy to control bleeding from ectopic varices?” <i>Journal of Hepatology</i> , 2017, 67, 202-203.	1.8	6
153	Ribavirin monotherapy for chronic hepatitis C. , 2005, , CD005527.		5
154	Agreement between Cochrane Neonatal Group reviews and clinical guidelines for newborns at a Copenhagen University Hospital – a cross-sectional study. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 96, 39-43.	0.7	5
155	Rifaximin for people with hepatic encephalopathy. <i>The Cochrane Library</i> , 0, , .	1.5	5
156	Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. <i>The Cochrane Library</i> , 2017, 7, CD002798.	1.5	5
157	Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor- α in patients with Crohn’s disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1155-1158.	0.8	5
158	Extracorporeal shock wave lithotripsy for pancreatic duct stones: an observational study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1399-1403.	0.6	5
159	Unravelling industry bias in clinical trials. <i>Pain</i> , 2006, 121, 175-176.	2.0	4
160	Hepato-biliary clinical trials and their inclusion in the Cochrane Hepato-biliary Group register and reviews. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 649-656.	1.4	4
161	The single-dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis. <i>British Journal of Dermatology</i> , 2014, 170, 408-414.	1.4	4
162	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. <i>BMJ Open</i> , 2014, 4, e005378-e005378.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Vaccines for preventing hepatitis B in healthcare workers (an updated protocol). The Cochrane Library, 0, , .	1.5	4
164	Cardiometabolic effects of antidiabetic drugs in non-€ alcoholic fatty liver disease. Clinical Physiology and Functional Imaging, 2019, 39, 122-127.	0.5	4
165	Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit. Pancreas, 2019, 48, e68-e70.	0.5	4
166	Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series. Medicina (Lithuania), 2020, 56, 565.	0.8	4
167	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Seminars in Liver Disease, 2021, 41, 235-247.	1.8	4
168	Treatment of hepatic encephalopathy: Authors' reply. BMJ: British Medical Journal, 2004, 329, 112.2.	2.4	4
169	Carvedilol versus non-selective beta-blockers for portal hypertension in cirrhosis. The Cochrane Library, 0, , .	1.5	3
170	Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy. The Cochrane Library, 0, , .	1.5	3
171	Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study. Nutrition, 2020, 69, 110574.	1.1	3
172	Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. World Journal of Gastroenterology, 2018, 24, 1650-1657.	1.4	3
173	Antioxidant Supplements and Mortality-€Reply. JAMA - Journal of the American Medical Association, 2007, 298, 400.	3.8	2
174	A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease. Case Reports in Gastroenterology, 2014, 8, 398-403.	0.3	2
175	Diets for primary prevention of gallbladder stones in adults. The Cochrane Library, 0, , .	1.5	2
176	L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy. The Cochrane Library, 0, , .	1.5	2
177	Banding ligation versus no intervention for primary prevention in adults with oesophageal varices. The Cochrane Library, 2017, , .	1.5	2
178	Severe hepatic encephalopathy is an independent predictor of mortality in hospitalised patients with cirrhosis. AME Medical Journal, 2017, 2, 134-134.	0.4	2
179	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. Journal of Hepatology, 2019, 70, e16-e17.	1.8	2
180	Pulmonary dysfunction due to combination of extra-pulmonary causes and alveolar damage is present from first the day of hospital admission in the early phase of acute pancreatitis. Pancreatology, 2019, 19, 519-523.	0.5	2

#	ARTICLE	IF	CITATIONS
181	Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 354-361.	0.4	2
182	Letter: the effects of rifaximin in hepatic encephalopathy - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 858-859.	1.9	1
183	Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. <i>The Cochrane Library</i> , 0, , .	1.5	1
184	Aminoglycosides and metronidazole for people with cirrhosis and hepatic encephalopathy. <i>The Cochrane Library</i> , 0, , .	1.5	1
185	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019, 114, S546-S546.	0.2	1
186	Fecal microbiota transplantation for treatment of irritable bowel syndrome. <i>The Cochrane Library</i> , 0, , .	1.5	1
187	Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 404.	1.0	1
188	Medical treatments for autoimmune hepatitis. <i>The Cochrane Library</i> , 0, , .	1.5	0
189	Antioxidants for liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1293-1294.	1.9	0
190	Letter: vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1104-1104.	1.9	0
191	Pharmacological interventions for the primary prevention of gallbladder stones in adults. <i>The Cochrane Library</i> , 2014, , .	1.5	0
192	Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices. <i>The Cochrane Library</i> , 0, , .	1.5	0
193	Bile acid derivatives for people with primary biliary cholangitis. <i>The Cochrane Library</i> , 0, , .	1.5	0
194	Effect of overweight and obesity on weight loss and length of stay in patients with walled-off pancreatic necrosis. <i>Nutrition</i> , 2017, 38, 109-112.	1.1	0
195	Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	0
196	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. <i>Journal of Hepatology</i> , 2019, 70, e17-e18.	1.8	0
197	SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients. <i>Journal of Hepatology</i> , 2019, 70, e663-e664.	1.8	0
198	551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB95.	0.5	0

#	ARTICLE	IF	CITATIONS
199	P: 9â€ŒPharmacotherapies that Specifically Target Ammonia for the Prevention and Treatment of Hepatic Encephalopathy in Adults With Crrhosis. American Journal of Gastroenterology, 2019, 114, S4-S4.	0.2	0
200	P: 51â€ŒAminoglycosides and Metronidazole for the Prevention and Treatment of Hepatic Encephalopathy in Adults With Cirrhosis. American Journal of Gastroenterology, 2019, 114, S26-S26.	0.2	0
201	Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis. Journal of Hepatology, 2020, 73, S207-S208.	1.8	0
202	Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study. Journal of Hepatology, 2020, 73, S439.	1.8	0
203	Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis. Journal of Hepatology, 2020, 73, S723-S724.	1.8	0
204	Tunnelated peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial. Journal of Hepatology, 2020, 73, S749-S750.	1.8	0
205	Aminoglycosides and metronidazole for the treatment of hepatic encephalopathy in adults with cirrhosis. Journal of Hepatology, 2020, 73, S756-S757.	1.8	0
206	Reply. When to stop non-selective beta-blockers: the window hypothesis in clinical practice. Journal of Gastrointestinal and Liver Diseases, 2014, 23, 458.	0.5	0
207	Lecture: Quality of Randomised Clinical Trials in Portal Hypertension and Other Fields of Hepatology. , 0, , 328-344.		0
208	Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis. World Journal of Hepatology, 2022, 14, 827-845.	0.8	0
209	Long-term changes of pancreatic function in patients with complicated walled-off necrosis. Scandinavian Journal of Gastroenterology, 2022, , 1-7.	0.6	0